NCT05080621

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

A Phase 1b/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Deciphera Pharmaceuticals, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Multicenter, open-label Phase 1b/2 study of ripretinib in combination with binimetinib in patients with gastrointestinal stromal tumor (GIST). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2).

Conditions

• Gastrointestinal Stromal Tumors

Interventions

Type	Name	Description
DRUG	Ripretinib	50 mg tablets
DRUG	binimetinib	15 mg tablets

Timeline

• Start date: 2021-11-01
• Primary completion: 2025-11-01
• Completion: 2027-05-01
• First posted: 2021-10-18
• Last updated: 2022-01-05

Regulatory

• FDA-regulated drug study